Drug General Information (ID: DDIDUMZHRP)
Drug Name			Urokinase		Drug Info		Cangrelor		Drug Info
Drug Type		Protein/peptide				Small molecule
Therapeutic Class		Thrombolytics				Antiplatelet Agents

Mechanism of Urokinase-Cangrelor Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Urokinase				Cangrelor
Mechanism		Risk of bleeding Thrombolytic agent				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Urokinase and Cangrelor

Recommended Action
Management		Caution is recommended if cangrelor must be used in patients treated with other agents that alter hemostasis. Patients should be monitored for potentially increased bleeding complications.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Kengreal (cangrelor). The Medicines Company, Parsippany, NJ.